Found: 29
Select item for more details and to access through your institution.
The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers.
- Published in:
- 2018
- By:
- Publication type:
- journal article
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
HIGH-DOSE <sup>131</sup>I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
- Published in:
- Radiation Protection Dosimetry, 2017, v. 173, n. 4, p. 395, doi. 10.1093/rpd/ncw030
- By:
- Publication type:
- Article
Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0052638
- By:
- Publication type:
- Article
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases.
- Published in:
- Sarcoma, 2008, p. 1, doi. 10.1155/2008/459386
- By:
- Publication type:
- Article
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 653, doi. 10.1007/s10637-010-9574-4
- By:
- Publication type:
- Article
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
- Published in:
- 2012
- By:
- Publication type:
- Report
Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 6, p. 1414, doi. 10.1007/s10637-010-9490-7
- By:
- Publication type:
- Article
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 700, doi. 10.1007/s10637-009-9315-8
- By:
- Publication type:
- Article
Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 839, doi. 10.1007/s10637-009-9317-6
- By:
- Publication type:
- Article
O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 6, p. 561, doi. 10.1007/s10637-008-9143-2
- By:
- Publication type:
- Article
Risk Factors for Early Catheter-related Infections in Cancer Patients.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 7, p. 1586, doi. 10.1002/cncr.22942
- By:
- Publication type:
- Article
Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Regorafenib use as a possible cause of intestinal perforation.
- Published in:
- 2013
- By:
- Publication type:
- Letter
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 3, p. 273, doi. 10.1007/s11523-013-0299-0
- By:
- Publication type:
- Article
Sorafenib in patients with progressive epithelioid hemangioendothelioma: A phase 2 study by the French Sarcoma Group (GSF/GETO)
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Sorafenib in patients with progressive epithelioid hemangioendothelioma Sorafenib in patients with progressive epithelioid hemangioendothelioma: A phase 2 study by the French Sarcoma Group (GSF/GETO).
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 14, p. 2639, doi. 10.1002/cncr.28109
- By:
- Publication type:
- Article
Erratum: Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. Nicolas P, Yazdan Y, Marie-Pierre C, Stéphanie C, Sylvia G, Jean-Charles N, Danièle L, Charles F, Jacques B. 2007. J Surg Oncol 96:124-129.
- Published in:
- Journal of Surgical Oncology, 2008, v. 97, n. 5, p. 479, doi. 10.1002/jso.20943
- By:
- Publication type:
- Article
Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection.
- Published in:
- Journal of Surgical Oncology, 2007, v. 96, n. 2, p. 124, doi. 10.1002/jso.20796
- By:
- Publication type:
- Article
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
- Published in:
- Oncology, 2016, v. 90, n. 2, p. 88, doi. 10.1159/000442947
- By:
- Publication type:
- Article
Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study.
- Published in:
- BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1225-x
- By:
- Publication type:
- Article
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.
- Published in:
- BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1143-y
- By:
- Publication type:
- Article
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.
- Published in:
- Medical Oncology, 2012, v. 29, n. 4, p. 3003, doi. 10.1007/s12032-012-0204-1
- By:
- Publication type:
- Article
Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 3, p. 143, doi. 10.1007/s40290-016-0138-6
- By:
- Publication type:
- Article
Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome.
- Published in:
- 2013
- By:
- Publication type:
- journal article